C-Suite Speaks
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
Launched in April 2025, Astellas’s Innovation Lab unites fragmented research units under Morten Sogaard to pursue focused indications, a dual-track R&D strategy and tailored partnerships that balance innovation, risk and collaboration.
Resmed’s CMO Carlos Nunez discusses the sleep giant’s continued push from medtech into healthtech and its efforts to fix what he calls a “broken pathway” to diagnosis and treatment for millions with undetected sleep apnea.
Aviv Regev is betting AI-driven drug discovery can transform Genentech's pipeline, with early wins validating her computational biology approach to pharmaceutical R&D.
Essential Pharma CEO Emma Johnson discusses the company’s strategic priorities and plans for growth as it expands its portfolio in rare diseases.
2026 is positioned as a breakout year for the psychedelic therapeutics sector, with multiple players expected to deliver defining Phase III results – creating momentum across the industry.
The recall of various Respironics sleep and respiratory care devices in 2021 plunged Philips into static growth and market share loss. Careful remediation is the group’s top priority, but S&RC head Dan Leonard is determined that the manner of its achievement will be the envy of the industry.
MediciNova and Coya Therapeutics are advancing ALS candidates as regulatory flexibility and Phase II pipeline concentration create a pivotal market inflection point.
Tris Pharma may be making headlines for its novel pain medication cebranopadol, but the New Jersey-based company's story extends far beyond a single asset.
The company’s approach leverages mPGES-1 inhibition to target both inflammation-related pain and lesion load. It is moving into a Phase II trial.
In the near future, “the US may no longer hold its position as the most important market,” says the CEO of a UK-based emerging biotech firm. Today’s biotech companies are shifting their growth strategies dramatically – moving away from reliance on a single dominant market.
How the seven-year-old biotech is building an industry-leading platform that is breaking the molecular glue dogma and could transform drug discovery.
ICROM on Flexibility, HPAPIs, and the Future of CDMO Services
Rapport Therapeutics CEO discusses the company's novel approach to AMPA modulation and why strategic externalization from J&J is accelerating neuroscience innovation.
ReproNovo's $65m Series A targets the $1.5bn male infertility market with the first potential oral therapy. Its first-in-class approach to underserved conditions like adenomyosis positions it as an attractive acquisition target in fertility's concentrated market.
Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.
Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.